Search results
Results from the WOW.Com Content Network
Complicated comorbidity: It is the result of the primary disease and often subsequent after sometime after its destabilization appears in the shape of target lesions (for example chronic nephratony resulting from diabetic nephropathy (Kimmelstiel-Wilson disease) in patients with type 2 diabetes; development of brain infarction resulting from ...
Autosomal dominant narcolepsy, obesity, and type 2 diabetes 347.00 G47.419 Narcolepsy without cataplexy but with hypocretin deficiency 347.01 G47.411 Narcolepsy with cataplexy but without hypocretin deficiency 347.10 G47.429 Narcolepsy secondary to another medical condition
A study suggested there is a paucity of multimorbidity and comorbidity data globally and mapped comorbidity patterns. [ 62 ] With aging populations , there is a rise of age-related diseases which puts major burdens on healthcare systems as well as contemporary economies or contemporary economics and their appendant societal systems.
Narcolepsy is a chronic neurological disorder that impairs the ability to regulate sleep–wake cycles, and specifically impacts REM (rapid eye movement) sleep. [1] The pentad symptoms of narcolepsy include excessive daytime sleepiness (EDS), sleep-related hallucinations, sleep paralysis, disturbed nocturnal sleep (DNS), and cataplexy. [1]
Depression was associated with diabetes in a 2010 longitudinal study of 4,263 individuals with type 2 diabetes, followed from 2005 to 2007. They were found to have a statistically significant association with depression and a high risk of micro and macro-vascular events.
[1] [35] The variant sleep-related eating disorders is chronic, without remission, but treatable. [35] REM sleep behavior disorder (RBD) can mostly be handled well with the use of melatonin or clonazepam. [25] [35] However, there is high comorbidity with neurodegenerative disorders, that is in up to 93% of cases. [35]
Carnitine has also been shown to improve narcolepsy symptoms (including daytime sleepiness) by increasing fatty-acid oxidation. [68] Abnormally low levels of acylcarnitine have been observed in patients with narcolepsy. [69] These same low levels have been associated with primary hypersomnia in general in mouse studies.
A score of zero means that no comorbidities were found; the higher the score, the higher the predicted mortality rate is. [2] [3] For a physician, this score is helpful in deciding how aggressively to treat a condition. It is one of the most widely used scoring system for comorbidities. [4]